Nivolumab Plus Ipilimumab for Metastatic Castration-Resistant Prostate Cancer: Preliminary Analysis of Patients in the CheckMate 650 Trial
Author:
Funder
Ono Pharmaceutical
Bristol-Myers Squibb
Publisher
Elsevier BV
Subject
Cancer Research,Cell Biology,Oncology
Reference55 articles.
1. Analysis of the prevalence of microsatellite instability in prostate cancer and response to immune checkpoint blockade;Abida;JAMA Oncol.,2019
2. Pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer: multicohort, open-label phase II KEYNOTE-199 study;Antonarakis;J. Clin. Oncol.,2020
3. Abiraterone alone or in combination with enzalutamide in metastatic castration-resistant prostate cancer with rising prostate-specific antigen during enzalutamide treatment;Attard;J. Clin. Oncol.,2018
4. IFN-gamma-related mRNA profile predicts clinical response to PD-1 blockade;Ayers;J. Clin. Invest.,2017
5. Enzalutamide in men with chemotherapy-naive metastatic castration-resistant prostate cancer: extended analysis of the phase 3 PREVAIL study;Beer;Eur. Urol.,2017
Cited by 216 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. The radiopharmaceutical radium-223 has immunomodulatory effects in patients and facilitates anti-programmed death receptor-1 therapy in murine models of bone metastatic prostate cancer;Radiotherapy and Oncology;2024-03
2. Tumor epitope spreading by a novel multivalent therapeutic cellular vaccine targeting cancer antigens to invariant NKT-triggered dendritic cells in situ;Frontiers in Immunology;2024-02-01
3. The future of targeting cytotoxic T-lymphocyte-associated protein-4: Is there a role?;European Journal of Cancer;2024-02
4. Novel Therapeutic Targets on the Horizon: An Analysis of Clinical Trials on Therapies for Bone Metastasis in Prostate Cancer;Cancers;2024-01-31
5. Germline DNA damage response gene mutations as predictive biomarkers of immune checkpoint inhibitor efficacy;Frontiers in Immunology;2024-01-29
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3